Phase I trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO)

Authors

John H. Stewart IV, Morehouse School of Medicine - Atlanta
Melissa Lowe, Duke Cancer Institute - Durham, NC
Andrew G. Chapple, LSU Health Sciences Center - New OrleansFollow
Donna Niedzwiecki, Duke Cancer Institute - Durham, NC
Ashley Moyer, Duke University - Durham, NC
Emily Bolch, Duke University - Durham, NC
Shannon Diane MacLaughlan, University of Illinois at Chicago
Edward A. Levine, Wake Forest University - Winston-Salem, NC
Omeed Moaven, LSU Health Sciences Center - New OrleansFollow
Niharika Nettu, Duke University - Durham, NC
John H. Strickler, Duke Cancer Institute - Durham, NC
Dan G. Blazer III, Duke University - Durham, NC

Document Type

Conference Proceeding

Publication Date

5-29-2024

Publication Title

Journal of Clinical Oncology

Abstract

Annual Meeting of the American Society of Clinical Oncology, 2024; May 21 - June 4, 2024; Chicago, IL

Volume

42

Issue

16

Comments

2668

Recommended Citation

Stewart, John H. IV; Lowe, Melissa; Chapple, Andrew G.; Niedzwiecki, Donna; Moyer, Ashley; Bolch, Emily; MacLaughlan, Shannon Diane; Levine, Edward A.; Moaven, Omeed; Nettu, Niharika; Strickler, John H.; and Blazer, Dan G. III, "Phase I trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO)" (2024). School of Medicine Faculty Publications. 3105.
https://digitalscholar.lsuhsc.edu/som_facpubs/3105
10.1200/JCO.2024.42.16_suppl.2668